Semaglutide, tirzepatide, and the next wave
What the class does well, common side effects, real-world adherence, compounding issues, and why the evidence is stronger here than almost anywhere else.
The honest, evidence-based companion to GLP-1 medications, recovery peptides, growth hormone secretagogues, gray-market sourcing, clinics, costs, regulation, and the risks most sales pages skip.
No subscription. No clinic pitch. Built as a reference for adults who want clarity before they make decisions.
GLP-1s became mainstream medicine. Recovery and anti-aging peptides became internet products. Telehealth clinics and research-chemical vendors turned a complex medical category into a checkout flow. This guide brings the evidence, risks, and regulatory reality back into view.
Understand which peptides have strong clinical evidence, which are experimental, and which are sold far beyond the data.
The book distinguishes FDA-approved use, human trials, limited clinical data, animal-only research, and marketing claims.
Compounded products, research chemicals, cold-chain handling, sterility, endotoxins, and third-party testing all get practical attention.
Premium clinic pricing, telehealth scripts, subscription models, and cheaper alternatives are compared without pretending every option is equal.
Use it once as a full read, then keep it as a reference when a peptide, clinic, stack, or claim shows up in your feed.
What the class does well, common side effects, real-world adherence, compounding issues, and why the evidence is stronger here than almost anywhere else.
The injury and recovery peptides get a sober review of mechanisms, animal data, limited human evidence, regulatory status, and practical risk.
Sermorelin, ipamorelin, CJC-1295, MK-677, IGF-1 analogues, and the cost-benefit gap between modest effects and aggressive marketing.
Research chemicals, compounding rules, FDA Category 2 concerns, international variation, import risk, sterility, endotoxin exposure, and source verification.
PT-141, semax, selank, epitalon, MOTS-c, cosmetic peptides, muscle claims, WADA concerns, and where the data thins out.
How to evaluate providers, what labs can and cannot tell you, stacking risks, contraindications, monitoring logic, and harm-reduction checklists.
The guide is direct about uncertainty. Strong evidence gets labeled strong. Weak evidence gets labeled weak. Gray-market risk gets treated as a real risk, not a footnote.
The book uses that frame throughout: serious about legitimate medicine, skeptical of grift, and explicit about the uncertainty around unapproved compounds.
This is for readers who want a premium, skeptical, evidence-aware reference before spending clinic money, ordering from a gray-market source, or trusting an influencer stack.
GLP-1s and approved prescription peptides are treated differently from claims based on early or animal-only evidence.
The guide names the long-term unknowns, thin evidence, and unstudied combinations that marketing tends to smooth over.
Quality, contamination, sterility, interactions, contraindications, cost, legal exposure, and athletic rules are handled directly.
Use the book to pressure-test a clinic, a protocol, a vendor, a social-media claim, or your own assumptions.
Regular price is $78. The launch sale gives you the complete 2026 edition with the full guide, peptide reference table, regulatory overview, lab-test appendix, source list, and harm-reduction checklist.
No. The guide is educational and cannot replace a clinician who knows your history. It is designed to help you understand the category, ask better questions, and recognize risk.
No. It explains what peptides are, where the evidence is strong or weak, what risks matter, and how different categories are regulated. Coverage does not mean endorsement.
No. GLP-1s receive deep coverage, but the book also covers BPC-157, TB-500, GHK-Cu, KPV, secretagogues, PT-141, cognitive peptides, performance peptides, skin and hair peptides, clinics, and sourcing.
Adults evaluating peptide claims, considering a prescription conversation, comparing clinic offers, researching gray-market risks, or trying to understand the peptide landscape without marketing distortion.
It gives you evaluation criteria, red flags, pricing context, source-quality questions, and risk categories to ask about. It does not certify or endorse specific providers.
The current sale price is $39 instead of $78. If peptides are already on your radar, the cost of one unclear clinic consult or one bad product decision can exceed the price of the guide.
Get the complete 2026 field guide for $39 while the sale is live.
Add to cart - go to checkout